Impact of Interferon-Based Treatment on Quality of Life and Work-Related Productivity of Korean Patients with Chronic Hepatitis C
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Chronic hepatitis C virus (HCV) infections put patients at risk of serious liver disease and adversely affects patient quality of life (QoL). MOSAIC (International Multicenter Prospective Observational Study to Evaluate the Epidemiology, Humanistic and Economic Outcomes of Treatment for Chronic Hepatitis C Virus) was a prospective, non-interventional, international, multicenter study that aimed to describe the epidemiology of the infection, the impact of the infection on health-related QoL (HRQoL) and daily activities, and healthcare resource use related to HCV and treatment. Here, we present the results on HRQoL and daily activity impairment in consecutively enrolled South Korean patients treated with interferon (IFN)-containing regimens prospectively followed for up to 48 weeks. Methods: General HRQoL, HCV-specific HRQoL, perceived health state, and work/general activity impairments were measured using the EuroQoL 5-dimension 5-level (EQ-5D-5L), HCV patient-reported outcomes (HCV-PRO), EQ-5D Visual Analog Scale, and Work Productivity and Activity Impairment questionnaires, respectively. Results: Thirty-three of the 100 enrolled patients initiated IFN-based treatment, with an intended duration of 24 weeks for 20 patients and 48 weeks for 12 patients; this information was missing for one patient. Fourteen patients (42.4%) prematurely withdrew. After treatment initiation, IFN-treated patients showed a trend towards deterioration of both general (baseline: 0.87±0.103, week 4: 0.77±0.153) and HCV-specific (baseline: 76.2±19.5, week 4: 68.2±22.3) HRQoL. The scores recovered somewhat towards the end of treatment (EOT) (0.84±0.146 for EQ-5D-5L and 70.8±21.9 for HCV-PRO). The perceived health state and work/general activity impairment displayed similar temporal patterns. Conclusions: Initiating IFN-based treatment prompted some deterioration in general and HCV-related HRQoL, accompanied by impaired daily activities and most work productivity measures; however, the HRQoL and productivity scores improved towards the EOT. HRQoL impairment upon treatment initiation likely contributed to treatment discontinuation.
Abstract
Background/Aims: Chronic hepatitis C virus (HCV) infections put patients at risk of serious liver disease and adversely affects patient quality of life (QoL). MOSAIC (International Multicenter Prospective Observational Study to Evaluate the Epidemiology, Humanistic and Economic Outcomes of Treatment for Chronic Hepatitis C Virus) was a prospective, non-interventional, international, multicenter study that aimed to describe the epidemiology of the infection, the impact of the infection on health-related QoL (HRQoL) and daily activities, and healthcare resource use related to HCV and treatment. Here, we present the results on HRQoL and daily activity impairment in consecutively enrolled South Korean patients treated with interferon (IFN)-containing regimens prospectively followed for up to 48 weeks. Methods: General HRQoL, HCV-specific HRQoL, perceived health state, and work/general activity impairments were measured using the EuroQoL 5-dimension 5-level (EQ-5D-5L), HCV patient-reported outcomes (HCV-PRO), EQ-5D Visual Analog Scale, and Work Productivity and Activity Impairment questionnaires, respectively. Results: Thirty-three of the 100 enrolled patients initiated IFN-based treatment, with an intended duration of 24 weeks for 20 patients and 48 weeks for 12 patients; this information was missing for one patient. Fourteen patients (42.4%) prematurely withdrew. After treatment initiation, IFN-treated patients showed a trend towards deterioration of both general (baseline: 0.87±0.103, week 4: 0.77±0.153) and HCV-specific (baseline: 76.2±19.5, week 4: 68.2±22.3) HRQoL. The scores recovered somewhat towards the end of treatment (EOT) (0.84±0.146 for EQ-5D-5L and 70.8±21.9 for HCV-PRO). The perceived health state and work/general activity impairment displayed similar temporal patterns. Conclusions: Initiating IFN-based treatment prompted some deterioration in general and HCV-related HRQoL, accompanied by impaired daily activities and most work productivity measures; however, the HRQoL and productivity scores improved towards the EOT. HRQoL impairment upon treatment initiation likely contributed to treatment discontinuation.
참고문헌 (20)
- Sebastiani G, "Chronic hepatitis C and liver fibrosis", World J Gastroenterol, 20, pp.11033~11053 (2014)
- Bonkovsky HL, "Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group", Hepatology, 29, pp.264~270 (1999)
- Ware JE Jr, "Health-related quality of life in chronic hepatitis C : impact of disease and treatment response. The Interventional Therapy Group", Hepatology, 30, pp.550~555 (1999)
- Spiegel BM, "Impact of hepatitis C on health related quality of life : a systematic review and quantitative assessment", Hepatology, 41, pp.790~800 (2005)
- "Hepatitis C: fact sheet" (2010)[URL]
- Petruzziello A, "Global epidemiology of hepatitis C virus infection : an up-date of the distribution and circulation of hepatitis C virus genotypes", World J Gastroenterol, 22, pp.7824~7840 (2016)
- Bennett H, "A review of the burden of hepatitis C virus infection in China, Japan, South Korea and Taiwan", Hepatol Int, 9, pp.378~390 (2015)
- 권근영, "Regional Distribution of Hepatitis C Virus Infection in the Republic of Korea, 2007-2011", Gut and Liver, 8(4), pp.428~432 (2014), 거트앤리버 소화기연관학회협의회
- Kim do Y, "Estimation of direct medical cost related to the management of chronic hepatitis C and its complications in South Korea", Medicine(Baltimore), 95, pp.e3896~ (2016)
- Korean Association for the Study of the Liver, "KASL clinical practice guidelines : management of hepatitis C", Clin Mol Hepatol, 22, pp.76~139 (2016)
- Korean Association for the Study of the Liver(KASL), "KASL clinical practice guidelines : management of hepatitis C", Clin Mol Hepatol, 20, pp.89~136 (2014)
- Herdman M, "Development and preliminary testing of the new five-level version of EQ-5D(EQ-5D-5L)", Qual Life Res, 20, pp.1727~1736 (2011)
- Janssen MF, "Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups : a multi-country study", Qual Life Res, 22, pp.1717~1727 (2013)
- Anderson RT, "Development and initial psychometric evaluation of the hepatitis C virus-patient-reported outcomes(HCV-PRO)instrument", Qual Life Res, 23, pp.561~570 (2014)
- Reilly MC, "The validity and reproducibility of a Work Productivity and Activity Impairment instrument", Pharmacoeconomics, 4, pp.353~365 (1993)
- Szende A, "Self-reported population health:an international perspective based on EQ-5D" (2014), Springer
- Kim SH, "The EQ-5D-5L valuation study in Korea", Qual Life Res, 25, pp.1845~1852 (2016)
- Hassanein T, "The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C", J Hepatol, 40, pp.675~681 (2004)
- Bernstein D, "Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients", Hepatology, 35, pp.704~708 (2002)
- Sabaté E, "Adherence to long-term therapies : evidence for action" (2003), World Health Organization